What Are The Main Advantages And Disadvantages Of Chinese Patent Law, And How Can Chinese Patent Law Best Be Improved?
DOI:
https://doi.org/10.61173/ihcs10902Keywords:
China’s Patent Law, patent protection, punitive damages, pharmaceutical patent linkage system, technological innovationAbstract
Taking China’s Patent Law as the research subject, this paper adopts secondary research and expert interviews to analyze its operation focusing on pharmaceutical and high-tech industries, supported by official statistical data and PEST analysis. The results show the patent system effectively stimulates research and development investment via market exclusivity and punitive damages, boosts industrial innovation and economic growth, and balances pharmaceutical innovation and public access to generic drugs. However, it suffers from low-quality idle patents, uneven regional enforcement, pharmaceutical patent evergreening, patent thickets, malicious litigation, and incomplete regulations for AI inventions. Targeted improvements are proposed, including optimized examination, differentiated punitive damages, overseas risk warning platforms, and supporting policies for SMEs. This study offers references for advancing high-quality intellectual property development.
References
Barnett J, Kappos D. Restoring deterrence: The case for enhanced damages in a no-injunction patent system[J]. Forthcoming in 5G and Beyond: Intellectual Property and Competition Policy in the Internet of Things (eds. Jonathan M. Barnett and Sean M. O'Connor, Cambridge University Press 2022), USC CLASS Research Paper No. CLASS22-2, USC Law Legal Studies Paper, 2022 (22-2).
Cao Y, Sun H. Analysis of Patents Awarded by Universities in China[J]. Forest Chemicals Review, 2022: 41-51.
China National Intellectual Property Administration. (2025, January 15). CNIPA Releases Key Figures for 2024 [Press release]. Retrieved from [http://www.cnipa.gov.cn.
Coussa A, Gugler P, Reidy J. Assessing the development of green innovation in China through patent evolution: the hallmark of government policy and private enterprises[J]. International Journal of Emerging Markets, 2025, 20(8): 3362-3386.
Feng, X. Q., & Luo, J. (2015). Research on punitive damages for intellectual property infringement: Humanistic spirit, institutional rationality and normative design. Journal of China University of Political Science and Law, (6), 37-38.
Fernandes P G L. Pharmaceutical innovation in healthcare: exploring open innovation models and biotechnology[D]. , 2024.
Ge, C. X. (2023). Pharmaceutical patent linkage system based on interest balance. China-Arab Science and Technology Forum (Chinese and English), (2), 143–147.
He, J. (2010). From green technology to green patent: Is a special patent system responding to climate change needed? Intellectual Property, (1), 39-41.
http://english.court.gov.cn/2024-03/22/c_90851.htm.
Huang C, Cao C, Coreynen W. Stronger and more just? Recent reforms of China’s intellectual property rights system and their implications[J]. Asia Pacific Journal of Innovation and Entrepreneurship, 2024, 18(3): 210-223.
Huang, X. F. (2003). Defining "original scope" in patent prior use rights. Electronic Intellectual Property.
Lemley M A, Reinecke J. Our More-Than-Twenty-Year Patent Term[J]. Berkeley Tech. LJ, 2024, 39: 681.
Li, C. H. (2017). Judicial system analysis of flaws and improvements in patent law. Legality Vision Journal, *2017*(11).
Li, M. R. (2025). Intellectual property boosting the development of new quality productivity: Mechanism of action and system optimization. Journal of the Party School of CPC Yinchuan Municipal Committee, (3), 63–72.
Li, X. Q., & Yu, C. (2022). On the establishment and improvement of the drug patent linkage system in the new "Patent Law". CNKI.
Li, Y. T. (2019). On the "prominent substantive features" requirement in the inventiveness of invention patents in China. China Invention & Patent, *16*(12), 67-72.
Liu Y, Zhang N, Xie C, et al. Evolution of drug regulations and regulatory innovation for anticancer drugs in China[J]. Acta Pharmaceutica Sinica B, 2022, 12(12): 4365-4377.
Liu Y. Punitive damages in Chinese patent law: Analysis of the Bayer v. Hengrui (2019) decision[J]. Journal of Intellectual Property Law & Practice, 2021, 16(7): 585-593.
Liu, X. (2025). Patent law responses to AI-era technological ethics. CNKI.
Liu, Y. L. (2022). Typological application and risk avoidance of punitive damages for intellectual property: From the perspective of international intellectual property rules. Chinese Journal of Law, *44*(1), 171-187.
Lv, M. L. (2023). Exploration of legal promotion mechanism for generic drug research and development from the perspective of pharmaceutical patents. Chinese Journal of Pharmaceuticals, *54*(7), 1142.
Ma, Z. F., & Xiao, Y. L. (2022). Construction of patent open sharing system under innovation-driven development strategy. Jianghan Academic, 41(1), 103-111.
Ma, Z. F., & Xie, D. Y. (2020). Research on punitive damages in patent law: From the perspective of the application of Article 72 of the Patent Law Amendment (Draft). Wuling Academic Journal, (2), 52-54.
Ministry of Science and Technology of the People's Republic of China. (2025). Report on China's Science and Technology Development 2024 [Annual work report]. Retrieved from https://www.most.gov.cn/eng/pressroom/.
Morris E M. The Unique World of Pharmaceutical Intellectual Property Rights[M]//Intellectual Property Law and Access to Medicines. Routledge, 2021: 379-404.
N/A. (2003, April 29). China ranks 2nd globally in life science patents. Science Times.
National Bureau of Statistics of China. (2024, February 29). Statistical Communiqué of the People's Republic of China on the 2023 National Economic and Social Development [Statistical communiqué]. Retrieved from http://www.stats.gov.cn/english/PressRelease/202402/t20240228_1947915.html.
Niu, Q. (2009). The "hindsight" in the judgment of patent "inventiveness": With comments on Article 22 of China's Patent Law and relevant provisions in the Examination Guidelines. Intellectual Property, *19*(4), 78-82.
Qi, J. G., & Zhang, S. H. (2023). New ideas for intellectual property legal system construction under innovation-driven development. Journal of Jishou University (Social Science Edition), *44*(6), 94-102. https://doi.org/10.13438/j.cnki.jdxb.2023.06.008.
Standing Committee of the National People's Congress of the People's Republic of China. (2023, December 29). Patent Law of the People's Republic of China (Amended) [Law, in Chinese]. Retrieved from http://www.npc.gov.cn/npc/c2/c30834/202312/t20231229_435048.html.
Sun M, Yin Y, Chen D, et al. Small molecules in lung cancer targeted therapy: a two-decade bibliometric analysis and visualization (2005–2024)[J]. Clinical Cancer Bulletin, 2025, 4(1): 13.
Supreme People's Court of the People's Republic of China. (2024, March). Work Report of the Supreme People's Court [Annual work report]. Delivered at the Second Session of the 14th National People's Congress.
Tu X. Disharmony in Patent Law: A Comparative Study of Patent Eligibility of Biological Subject Matters Between China and the United States[J]. Cybaris Intell. Prop. L. Rev., 2024, 15: 63.
United States Patent and Trademark Office.Speaking Engagements | USPTO[PDF/OL].[https://www.uspto.gov/sites/default/files/documents/AIPLA_2016_Slides.pdf.
Wang, A. N. (2023). Transformation of green technology patent licensing model from the perspective of regulation theory. Journal of Political Science and Law, *40*(3), 40-51.
Wang, J., & Li, J. X. (2021). Multiple obstacles and solutions to the implementation of compulsory licensing system for green technology patents in China. Environmental Protection, (1), 47-48.
Wang, M. L., & Tan, C. (2017). Challenge and response: The future of China's pharmaceutical patent system—From the perspective of the relationship between pharmaceutical patents and health rights. Intellectual Property, (2), 41-47.
Wei, C., Tian, T., Du, G. S., et al. (2021). System design of early resolution mechanism for pharmaceutical patent disputes with Chinese characteristics: From the perspective of comparison between foreign experience and domestic situation. Chinese Journal of New Drugs, *30*(15), 1345–1354.
World Intellectual Property Organization. (2023). World Intellectual Property Indicators 2023 [Annual report]. https://www.wipo.int/publications/en/details.jsp?id=4690.
Wu, H. D. (2008). Multi-dimensional interpretation of intellectual property rights. Peking University Press.
Xia N. Pharmaceutical industry influence, traditional medical knowledge, and the evolution of ip governance in china[M]//Medicinal Mandates: The Intersection of Chinese Traditional Medical Knowledge and Modern Law. Singapore: Springer Nature Singapore, 2025: 159-201.
Xiao, Y. L. (2022). On the construction of patent open sharing system: Drawing lessons from open source software. Electronic Intellectual Property, (7), 4-15.
Xu, C. M. (2025). Analysis of development layout of new energy vehicle manufacturing enterprises under the background of carbon neutrality: A case study of Tesla Shanghai Gigafactory expansion. Modern Industrial Economy and Informationization, *15*(4), 223-225+232. https://doi.org/10.16525/j.cnki.14-1362/n.2025.04.076.
Yi, J. M. (2017). The transformation of patent law: From dualistic to triadic structure. Faxue Zazhi (Law Science Magazine), *2017*(7), 41–51.
Yue, Z. Q., & Liu, L. (2023). Research on patent open-source strategy and risk prevention. Intellectual Property, (2), 91–111.
Yue, Z. Q., & Liu, L. (2023). Research on patent open-source strategy and risk prevention. Intellectual Property, (2), 91-111.
Yuejun W, Yue Y, Zhe H. Research on Incentive Policies for Chinese Innovative Drug R&D-Taking Innovative Anti-tumor Drugs as an Example[J]. Asian Social Pharmacy, 2023, 18(4): 303-314.
Zeng, L. (2011). Adjustments in the judgment of patent non-obviousness in the United States and its enlightenment to China [Master's thesis, East China University of Political Science and Law].
Zhang H L, Li Y. Recent development of drugs for osteoporosis and anti-cancer agents: A patent analysis[J]. Pharmaceutical Patent Analyst, 2021, 10(2): 73-82.
Zhang H, Lou Y, Cai K. Research on the dilemma and improvement of legal regulation for unfair competition related to corporate data in China[J]. Computer Law & Security Review, 2021, 42: 105582.
Zhang, G. L. (2020). The construction of punitive damages system for intellectual property. Law Science, (5), 127-130.
Zhang, H. R., & Fu, A. Z. (2024). Evaluation and proposed enhancements for the Pharmaceutical Patent Linkage System under the Patent Law. Intellectual Property Studies.
Zhang, P. (2017). The principles and practices of "amendments beyond original scope" in patent law. Tsinghua Intellectual Property Review.
Zhang, W. J., & Zhang, W. W. (2019). Research on punitive damages for patent infringement. Science & Technology Progress and Policy, *36*(20), 121-127.
Zhao Y. Legal environment, technological innovation, and sustainable economic growth[J]. Frontiers in Psychology, 2022, 13: 929359.
Zhou Y, Sun F. Creating knowledge assets under biocapitalism: Analyzing China’s biomedical industry and its patent networks[J]. Economic Geography, 2022, 98(5): 411-437.
Zhou, L. F. (2011). On the examination standards for patent non-obviousness [Master's thesis, East China University of Political Science and Law].
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
